nl003
Gene therapyexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01548378)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factorSupplementation
HGF supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- nl003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05968118 | Phase 3 | Jul 29, 2022 | Beijing Northland Biotech. Co., Ltd. |
| NCT04274049 | Phase 3 | Aug 18, 2019 | Beijing Northland Biotech. Co., Ltd. |
| NCT04275323 | Phase 3 | Aug 2, 2019 | Beijing Northland Biotech. Co., Ltd. |
| NCT01548378 | Phase 2 | Mar 1, 2012 | Beijing Northland Biotech. Co., Ltd., ViroMed |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Northland Biotech. Co., Ltd. | For profit | 4 | 4 | 2 | 2012 |
| ViroMed | For profit | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1